ALTHX THX Pharma Société Anonyme

3.532USD3.220 EUR · EPA-1.98%Mkt Cap: 51.17M USDP/E: —

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug…

Key Statistics

Company
Market Cap51.17M USD
Enterprise Value35.07M USD
Revenue (TTM)3.57M USD
Gross Profit-2.57M USD
Net Income (TTM)-3.29M USD
Revenue/Share0.25 USD
Last Price3.532 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0013286259
Valuation
P/E (Trailing)—
P/E (Forward)-1.75
PEG—
EV/EBITDA-9.06
EV/Revenue9.82
P/S14.33
P/B15.71
EPS (TTM)-0.23 USD
EPS (Forward)-2.02 USD
52W Range
1.63448% of range5.594
52W High5.594 USD
52W Low1.634 USD
Profitability
Gross Margin-5.04%
Oper. Margin-112.00%
EBITDA Margin-108.36%
Profit Margin-62.35%
ROE-103.45%
ROA-28.46%
ROIC—
ROCE-87.74%
Growth
Revenue Growth303.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-901.13K USD
CapEx (TTM)282.13K USD
FCF Margin-125.37%
FCF Yield-8.75%
Net Debt-16.30M USD
Net Debt/EBITDA4.21
Net Debt/FCF—
Balance Sheet
Debt/Equity0.99
Current Ratio5.83
Quick Ratio5.77
Book Value/Sh0.22 USD
Cash/Share1.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.361 USD
Upside (mean)+80.1%
Target Range6.361 USD – 6.361 USD
# Analysts1
Ownership
Shares Out.14.49M
Float11.60M
Insiders12.84%
Institutions19.74%
Technical
SMA 503.610 (-2.2%)
SMA 2003.830 (-7.8%)
Beta1.47
S&P 52W Chg12.00%
Avg Vol (30d)41.34K
Avg Vol (10d)47.02K
Technical Indicators
RSI (14)46.2
MACD-0.0190
MACD Signal-0.0085
MACD Hist.-0.0104
BB Upper3.866 USD
BB Middle3.641 USD
BB Lower3.416 USD
BB Width12.34%
ATR (14)0.1726 USD
Vol Ratio (20d)0.72x

About THX Pharma (EPA: ALTHX)

›

THX Pharma (EPA: ALTHX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.

The shares were at 3.220 EUR on 19 November 2026, up 92.2% over 52 weeks. Its 52-week range is 1.490 EUR to 5.100 EUR: the price is 36.9% below the high and 116.1% above the low.

Its market capitalisation is 46.65M EUR.

THX Pharma reports return on equity of -103.5%, an operating margin of -112.0% and revenue up 303.9% year over year.

It holds more cash than debt, a net cash position of 14.86M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.800 EUR is 80.1% above the current price.